These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 11469866)

  • 1. Polyglutamine aggregation behavior in vitro supports a recruitment mechanism of cytotoxicity.
    Chen S; Berthelier V; Yang W; Wetzel R
    J Mol Biol; 2001 Aug; 311(1):173-82. PubMed ID: 11469866
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A linear lattice model for polyglutamine in CAG-expansion diseases.
    Bennett MJ; Huey-Tubman KE; Herr AB; West AP; Ross SA; Bjorkman PJ
    Proc Natl Acad Sci U S A; 2002 Sep; 99(18):11634-9. PubMed ID: 12193654
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polyglutamine expansion mutation yields a pathological epitope linked to nucleation of protein aggregate: determinant of Huntington's disease onset.
    Sugaya K; Matsubara S; Kagamihara Y; Kawata A; Hayashi H
    PLoS One; 2007 Jul; 2(7):e635. PubMed ID: 17653262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imaging polyglutamine deposits in brain tissue.
    Osmand AP; Berthelier V; Wetzel R
    Methods Enzymol; 2006; 412():106-22. PubMed ID: 17046655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of chain length on the aggregation of model polyglutamine peptides: molecular dynamics simulations.
    Marchut AJ; Hall CK
    Proteins; 2007 Jan; 66(1):96-109. PubMed ID: 17068817
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Huntington's disease age-of-onset linked to polyglutamine aggregation nucleation.
    Chen S; Ferrone FA; Wetzel R
    Proc Natl Acad Sci U S A; 2002 Sep; 99(18):11884-9. PubMed ID: 12186976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time-lapse analysis of aggregate formation in an inducible PC12 cell model of Huntington's disease reveals time-dependent aggregate formation that transiently delays cell death.
    Gong B; Lim MC; Wanderer J; Wyttenbach A; Morton AJ
    Brain Res Bull; 2008 Jan; 75(1):146-57. PubMed ID: 18158109
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reconsidering the mechanism of polyglutamine peptide aggregation.
    Lee CC; Walters RH; Murphy RM
    Biochemistry; 2007 Nov; 46(44):12810-20. PubMed ID: 17929830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of polyglutamine aggregate cytotoxicity by a structure-based elongation inhibitor.
    Thakur AK; Yang W; Wetzel R
    FASEB J; 2004 May; 18(7):923-5. PubMed ID: 15001566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Familial frontotemporal dementia with neuronal intranuclear inclusions is not a polyglutamine expansion disease.
    Mackenzie IR; Butland SL; Devon RS; Dwosh E; Feldman H; Lindholm C; Neal SJ; Ouellette BF; Leavitt BR
    BMC Neurol; 2006 Aug; 6():32. PubMed ID: 16945149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oligoproline effects on polyglutamine conformation and aggregation.
    Bhattacharyya A; Thakur AK; Chellgren VM; Thiagarajan G; Williams AD; Chellgren BW; Creamer TP; Wetzel R
    J Mol Biol; 2006 Jan; 355(3):524-35. PubMed ID: 16321399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modeling the polyglutamine aggregation pathway in Huntington's disease: from basic studies to clinical applications.
    Sugaya K
    Subcell Biochem; 2012; 65():353-88. PubMed ID: 23225011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Molecular biology of polyglutamine diseases].
    Owecki M; Kozubski W
    Postepy Hig Med Dosw; 2002; 56(6):779-88. PubMed ID: 12661407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CAG repeat disorder models and human neuropathology: similarities and differences.
    Yamada M; Sato T; Tsuji S; Takahashi H
    Acta Neuropathol; 2008 Jan; 115(1):71-86. PubMed ID: 17786457
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteasome degrades soluble expanded polyglutamine completely and efficiently.
    Michalik A; Van Broeckhoven C
    Neurobiol Dis; 2004 Jun; 16(1):202-11. PubMed ID: 15207277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amyloid-like features of polyglutamine aggregates and their assembly kinetics.
    Chen S; Berthelier V; Hamilton JB; O'Nuallain B; Wetzel R
    Biochemistry; 2002 Jun; 41(23):7391-9. PubMed ID: 12044172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spontaneous formation of polyglutamine nanotubes with molecular dynamics simulations.
    Laghaei R; Mousseau N
    J Chem Phys; 2010 Apr; 132(16):165102. PubMed ID: 20441310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Huntington's disease: revisiting the aggregation hypothesis in polyglutamine neurodegenerative diseases.
    Truant R; Atwal RS; Desmond C; Munsie L; Tran T
    FEBS J; 2008 Sep; 275(17):4252-62. PubMed ID: 18637947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Length dependence of the coil <--> beta-sheet transition in a membrane environment.
    Meier M; Seelig J
    J Am Chem Soc; 2008 Jan; 130(3):1017-24. PubMed ID: 18163629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The advances in research on phosphorylation of polyglutamine disease].
    Zhou YF; Jiang H; Tang JG; Tang BS
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Aug; 25(4):414-7. PubMed ID: 18683139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.